RxDoctor Payments DataLook up a doctor →

Heather Finlayson, PA

Physician Assistant · Littleton, CONPI 1952480873

Payments from drug & device makers

$180,329in general payments, 2019–2025

Across 865 payments — averaging $208.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$44K
  • Sanofi$37K
  • UCB, Inc.$28K
  • GSK$28K
  • Johnson & Johnson$23K
  • Boehringer Ingelheim$5K
  • plus $16K from 28 others

What the payments were for

  • Consulting fees$23,08713%
  • Speaking & faculty fees$104,35858%
  • Travel & lodging$28,15016%
  • Food & beverage$24,50114%
  • Education$2330%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$180,329 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$182,840
Medicare patients
135
Services billed
5,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab43$429,141
Enbrel SureclickEtanercept19$197,769
Cosentyx Unoready PenSecukinumab15$128,311
Orencia ClickjectAbatacept14$92,810
BenlystaBelimumab16$77,599
Humira PenAdalimumab11$69,004
Hydroxychloroquine Sulfate101$3,696
Cevimeline Hcl19$2,562
MethotrexateMethotrexate Sodium62$1,937
Leflunomide12$692
Prednisone61$610
Folic Acid17$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$27,917$77,59916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →